20
Participants
Start Date
May 31, 2006
Primary Completion Date
December 31, 2010
Study Completion Date
December 31, 2010
ranibizumab 0.5 or 0.3 mg/0.05 cc
ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician
Southeast Retina Center, Augusta
Collaborators (1)
Genentech, Inc.
INDUSTRY
Southeast Retina Center, Georgia
OTHER